10-Q: Aditxt Faces Going Concern Doubt Amid Mounting Losses

Aditxt, Inc. reported a significant net loss and negative cash flow for Q2 2025, raising substantial doubt about its ability to continue as a going concern, despite recent capital raises.

Summary

• Reported a net loss of $13,348,123 for the six months ended June 30, 2025, compared to $22,492,573 for the same period in 2024.
• Cash balance stood at $323,679 as of June 30, 2025, a decrease from $833,031 at December 31, 2024.
• Revenue for the six months ended June 30, 2025, plummeted to $2,022 from $123,956 in the prior year, primarily due to decreased COVID testing for AditxtScore™.
• Operating cash flow was negative $14,098,132 for the six months ended June 30, 2025, worsening from negative $8,250,807 in the prior year.
• Working capital deficit was $(20,148,964) as of June 30, 2025.
• Multiple debt agreements, including the November Loan Agreement, January Loan Agreement, and May 2025 Note, are in default status as of June 30, 2025.
• All lab equipment financing agreements have matured and are in default status as of June 30, 2025.
• The lease for the Richmond, Virginia facility is two months in arrears as of June 30, 2025.
• The Arrangement Agreement with Appili was terminated, resulting in a $1,250,000 termination fee, with $1,000,000 remaining unpaid as of June 30, 2025.
• Regained compliance with Nasdaq's minimum bid price requirement on April 8, 2025, but continued compliance is not assured.
• Continued development of ADI-100 for autoimmune diseases, with preclinical studies completed and human trials for Stiff Person Syndrome expected in 2025.
• Pearsanta subsidiary is developing Mitomic Prostate Test (MPT) and Mitomic Endometriosis Test (MET) for early cancer detection, and acquired Adductomics Technology for DNA adduct analysis.
• The acquisition of Cellvera's interest in G Response Aid FZE (Avigan license) is unlikely to be completed due to Cellvera's liquidation.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by a 'going concern' doubt, significant operating losses, declining revenue, multiple debt defaults, and a substantial working capital deficit. While capital raises have occurred, they appear insufficient to stabilize the company's long-term financial health, and key strategic initiatives are facing delays or termination.

Positives

• Net loss decreased to $13,348,123 for the six months ended June 30, 2025, from $22,492,573 in the prior year period.
• Net loss per share improved significantly to $(9.22) for the six months ended June 30, 2025, from $(3,262.64) in the prior year, partly due to reverse stock splits.
• Total stockholders' equity improved to $11,994,864 as of June 30, 2025, from a deficit of $(86,604) at December 31, 2024, driven by financing activities.
• Regained compliance with Nasdaq's minimum bid price requirement on April 8, 2025.
• Preclinical studies for ADI-100 (immune modulation therapeutic) have been completed, and GMP clinical-grade drug substances have been successfully manufactured.
• Human trials for Stiff Person Syndrome using ADI-100 are expected to get underway in 2025.
• Pearsanta acquired Adductomics Technology, expanding its pipeline for early cancer risk identification.

Negatives

• Substantial doubt exists about the ability to continue as a going concern beyond one year due to significant operating losses and insufficient cash reserves.
• Cash balance decreased to $323,679 as of June 30, 2025, from $833,031 at December 31, 2024.
• Revenue for the six months ended June 30, 2025, was only $2,022, a drastic reduction from $123,956 in the same period last year, attributed to decreased COVID testing.
• Negative cash flow from operating activities worsened to $(14,098,132) for the six months ended June 30, 2025, from $(8,250,807) in the prior year.
• Working capital deficit remains substantial at $(20,148,964) as of June 30, 2025.
• Multiple significant debt agreements are in default status, including the November Loan Agreement ($560,268 principal), January Loan Agreement ($2,000,336 principal), and May 2025 Note ($1,114,286 principal).
• All lab equipment financing agreements have matured and are in default.
• The Richmond, Virginia lease is two months in arrears, and the company is working with the landlord for resolution.
• The Arrangement Agreement with Appili was terminated, incurring a $1,250,000 termination fee, with $1,000,000 still outstanding.
• Missed milestone payments and clinical trial deadlines for the LLU License Agreement, requiring extensions.
• The proposed acquisition of Cellvera's interest in G Response Aid FZE (Avigan license) is unlikely to be completed due to Cellvera's liquidation.
• Material weaknesses in internal control over financial reporting and disclosure controls were identified and persist as of June 30, 2025.

Risks

• Substantial doubt about the ability to continue as a going concern due to a limited operating history, no significant revenue from commercial sales, and recurring net losses.
• Inability to obtain necessary capital to fund operations and product development, leading to potential loss of entire investment.
• Risk of delisting from Nasdaq, which could adversely affect stock value, liquidity, and ability to obtain financing.
• Currently over 90 days past due on approximately $5.7 million in vendor obligations, and risk of default on substantial indebtedness.
• Secured creditors could foreclose on assets if the company defaults on obligations, potentially forcing bankruptcy.
• Significant dilution risk from the issuance and sale of common stock under the At The Market Offering Agreement (up to $35 million) and the Common Stock Purchase Agreement (up to $150 million).
• The regulatory approval process for product candidates is expensive, time-consuming, and uncertain.
• Potential for substantial delays or failure in completing clinical studies, leading to additional costs or inability to obtain regulatory approval.
• Inability to successfully commercialize product candidates even if regulatory approval is received.
• Adverse events involving products could lead to regulatory delays, denials, or product recalls.
• Licenses from Loma Linda University (LLU) and Stanford are revocable if certain payments and milestone deadlines are not met.
• Loss of CLIA certification or state laboratory licenses would prevent offering assays like AditxtScore, harming revenue and business.
• Exposure to substantial competition from larger, more well-funded companies.
• Failure to obtain or maintain patents, licensing agreements, and other intellectual property could materially impact competitive ability.
• Uncertainty regarding the consummation or accretive value of the merger agreement with Evofem Biosciences, Inc.
• Future acquisitions or strategic transactions may require additional financing, increase expenses, or distract management.
• Exclusive forum provisions in corporate documents may limit shareholders' ability to bring certain actions.

Future Outlook

The company explicitly states that its financial situation creates substantial doubt about its ability to continue as a going concern beyond one year. It anticipates incurring additional net expenses for the foreseeable future and does not expect to achieve profitability soon. The ability to raise future capital is dependent on market conditions and clinical development progress, with no assurance that funding will be available on acceptable terms or at all. Delays, scaling back, or elimination of planned development, including clinical trials, may be necessary if funds are insufficient. The company intends to obtain an extension to commence human trials for ADI technology by September 30, 2025. Human trials for Stiff Person Syndrome are expected to get underway in 2025. Pearsanta anticipates additional development over the next two to three years for its Adductomics Technology platform.

Management Comments

• "We believe our remaining funds on hand will not be sufficient to fund our operations for the next 12 months and such creates substantial doubt about our ability to continue as a going concern beyond one year."
• "The Company continues to actively pursue numerous capital raising transactions with the objective of obtaining sufficient bridge funding to meet the Companys existing capital needs as well as more substantial capital raises to meet the Companys longer-term needs."
• "We expect to incur additional net expenses over the next several years as we continue to maintain and expand our existing operations. The amount of future losses and when, if ever, we will achieve profitability are uncertain."
• "The decrease in revenue and costs of goods sold during the three and six months ended June 30, 2025 compared to the three and six months ended June 30, 2024 was due to a decrease in AditxtScore™ orders due to decreased COVID testing being done."
• "The Company intends to obtain an extension to commence human trials by September 30, 2025."
• "The Company does not presently believe that the proposed acquisition of Cellvera will be completed as proposed or at all."

Industry Context

Aditxt operates in the highly capital-intensive and competitive biotechnology and diagnostics sectors, focusing on immune modulation, early cancer detection, and antivirals. The significant decline in AditxtScore revenue due to decreased COVID testing highlights the volatility of relying on specific market demands. The ongoing need for substantial capital to fund clinical trials and product development is typical for early-stage biotech firms, but Aditxt's severe liquidity issues, multiple debt defaults, and termination of a key acquisition (Appili) suggest a struggle to navigate this environment effectively. The pursuit of immune tolerance therapies (ADI-100) and mitochondrial DNA-based cancer diagnostics (Pearsanta) aligns with high-growth areas in precision medicine, but the company's financial instability poses a significant barrier to realizing the potential of these innovations.

Comparison to Industry Standards

• The company's revenue of $2,022 for six months is exceptionally low for a publicly traded biotechnology company, indicating minimal commercial traction compared to industry peers that typically generate millions or billions in revenue from commercialized products or significant R&D grants.
• A working capital deficit of over $20 million and a cash balance of $323,679 are far below industry standards for companies engaged in active R&D and clinical trials, which typically require substantial cash reserves to sustain operations for multiple years.
• The explicit 'going concern' doubt and multiple debt defaults are critical indicators of severe financial distress, placing the company significantly below the financial health benchmarks of stable biotech firms or even many early-stage ventures.
• The high interest rates (e.g., 49% on November and January loans) and significant original issue discounts on debt indicate a high-risk borrowing profile, far exceeding typical financing costs for companies with more stable financial positions.
• The termination of the Appili Arrangement Agreement and the unlikelihood of the Cellvera acquisition suggest challenges in executing strategic partnerships and M&A, which are common growth avenues in the biotech industry.
• While the development of ADI-100 and Mitomic Technology addresses high-need areas, the company's inability to meet clinical trial milestones and secure consistent funding for these programs places it behind competitors with more robust pipelines and financial backing, such as larger pharmaceutical companies or well-funded clinical-stage biotechs like Moderna (mRNA vaccines) or Exact Sciences (Cologuard for cancer screening) which have established revenue streams or significant capital reserves.

Corporate Governance

Legal Proceedings

• The company may become involved in various lawsuits and legal proceedings in the ordinary course of business, with inherent uncertainties that could harm the business.

Related Party Transactions

• Amro Albanna (CEO) loaned $233,000 to the company on May 22, 2025, repaid by June 30, 2025.
• Shahrokh Shabahang (CIO) loaned $70,000 to the company on June 6, 2025, repaid by June 30, 2025.
• Amro Albanna (CEO) and Shahrokh Shabahang (CIO) loaned $90,000 and $100,000 respectively to the company on June 20, 2025, repaid by June 30, 2025.
• The company purchased a senior subordinated convertible note (Evofem April Note) in the principal amount of $2,307,692 and a warrant from Evofem for $1,500,000 on April 8, 2025. Evofem is a related party due to its CEO being on Aditxt's Board of Directors.
• The company purchased a senior subordinated convertible note (Evofem June Note) in the principal amount of $1,423,077 and a warrant from Evofem for $925,000 on June 26, 2025.
• Amro Albanna (CEO) and Shahrokh Shabahang (CIO) each loaned $95,000 to the company on August 13, 2025.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing equity offerings (ATM, ELOC) and potential downward pressure on stock price due to financial distress, debt defaults, and 'going concern' doubt. The value and liquidity of common stock, warrants, and pre-funded warrants are likely to be adversely affected if delisted from Nasdaq.
• **Creditors**: Secured and unsecured lenders face high risk due to multiple debt defaults and the company's precarious financial position, with secured creditors having the right to foreclose on assets.
• **Employees**: Uncertainty regarding the company's future operations and financial stability could impact job security and morale.
• **Customers**: Decreased AditxtScore™ orders due to reduced COVID testing indicate a decline in service demand, potentially impacting future revenue streams.
• **Partners (LLU, Stanford)**: Missed milestone payments and clinical trial deadlines could strain licensing agreements and potentially lead to their revocation, impacting product development.

Next Steps

• Actively pursue numerous capital raising transactions to obtain sufficient bridge funding and longer-term capital.
• Continue efforts to remain compliant with Nasdaq listing requirements.
• Work with the landlord to resolve the two-month arrears on the Richmond, Virginia lease.
• Seek an extension for the missed September 30, 2024, milestone payment to Loma Linda University.
• Actively pursue an extension for the completion of first-in-human (Phase I/II) clinical trials, which was due by September 30, 2024.
• Obtain an extension to commence human trials for ADI technology by September 30, 2025.
• Hold a pre-IND meeting with the FDA for ADI-100 in Q2 2025.
• Initiate a human trial for Stiff Person Syndrome with 10-20 patients in 2025, pending regulatory approvals.
• Continue technical development and clinical validation for Mitomic Prostate Test (MPT) and Mitomic Endometriosis Test (MET).
• Pursue biomarker identification for pancreatic, liver, breast, stomach, esophageal, and colorectal cancers.
• Further validate and develop the Adductomics Technology platform over the next two to three years toward clinical and commercial applications.
• Remediate identified material weaknesses in internal control over financial reporting and disclosure controls.

Key Dates

Recommendation

The company's financial condition is extremely precarious, with explicit 'substantial doubt' about its ability to continue as a going concern. Key indicators include a critically low cash balance ($323,679), a massive working capital deficit (over $20 million), and a drastic 98% decline in revenue for the six months ended June 30, 2025. Multiple debt agreements are in default, and a significant termination fee is owed from a failed acquisition. While capital raises have occurred, they appear to be short-term solutions that are highly dilutive and have not fundamentally addressed the underlying financial instability. The ongoing material weaknesses in internal controls further compound the risk. Given the severe liquidity issues, high operational burn rate, and significant risk of delisting or bankruptcy, a seasoned investor would likely recommend a strong sell to minimize further losses.

Keywords

Biotechnology, Immunotherapy, Cancer Diagnostics, Autoimmune Diseases, SEC Filing, 10-Q, Financial Reporting, Going Concern, Clinical Trials, Capital Raise, Nasdaq Listing, Debt Default, AditxtScore, Mitomic Technology, ADI-100, Evofem, Appili